Cambridge, Mass. — Takeda said new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology Congress, being held Oct. 23-27 in Madrid.
The presentations will include late-breaking Phase 3 data on arcotatug tavatecan, also known as TAK-921, in previously treated advanced gastric cancer, as well as new findings for TAK-928 in non-small cell lung cancer.
“Takeda’s data at ESMO reflect our commitment to delivering rapid progress for patients living with some of the most prevalent and challenging cancers, including advanced gastric cancer and immunotherapy-resistant and previously untreated non-small cell lung cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda.
“Our mission is to advance new therapeutic approaches for patients who need more options or who remain underserved by current standards of care. Together, our late-stage oncology pipeline and portfolio of thoracic and gastrointestinal cancer medicines are helping address patients’ needs today while building possibilities for the future,” Morrow added.
Late-breaking data from the Phase 3 G-HOPE-001 study of arcotatug tavatecan will be presented Oct. 23. The study is being conducted in Japan and China in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.
Arcotatug tavatecan is an investigational Claudin 18.2-targeted antibody-drug conjugate designed to deliver an exatecan payload. Takeda said results from the study could support a potential regulatory filing in Japan, depending on the final data.
Takeda will also present new findings on TAK-928 in non-small cell lung cancer, including results for TAK-928 combined with bevacizumab in patients whose disease is resistant to immunotherapy and TAK-928 combined with chemotherapy in previously untreated patients.
TAK-928 is an investigational PD-1/alpha-biased IL-2 bispecific fusion protein. Takeda is evaluating the drug in the global Phase 3 MarsLight-11 study against docetaxel in patients with squamous non-small cell lung cancer whose disease has progressed during or after chemotherapy and immunotherapy.
Enrollment is underway globally, including in the United States. Takeda said it is also adding a new sub-trial for patients with non-squamous non-small cell lung cancer.
Additional ESMO presentations will include clinical and real-world analyses of Takeda’s approved oncology medicines ALUNBRIG, or brigatinib, and FRUZAQLA, or fruquintinib.
Arcotatug tavatecan and TAK-928 remain investigational and have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.
